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Application of a low molecular weight antifungal
protein from Penicillium chrysogenum (PAF) to treat
pulmonary aspergillosis in mice
Zoltán Palicz1, Tamás Gáll1, Éva Leiter2, Sándor Kollár3, Ilona Kovács3, Kornél Miszti-Blasius4, István Pócsi2,
László Csernoch1 and Péter Szentesi1
PAF, a small antifungal protein from Penicillium chrysogenum, inhibits the growth of several pathogenic filamentous fungi,
including members of the Aspergillus genus. PAF has been proven to have no toxic effects in vivo in mice by intranasal
application. To test its efficacy against invasive pulmonary aspergillosis (IPA), experiments were carried out in mice suffering
from IPA. Adult mice were immunosuppressed and then infected with Aspergillus fumigatus. After stable infection, the animals
were inoculated with PAF intranasally at a concentration of 2.7 mg/kg twice per day. At this concentration—which is highly toxic
in vitro to A. fumigatus—the mortality of the animals was slightly delayed but finally all animals died. Histological examinations
revealed massive fungal infections in the lungs of both PAF-treated and untreated animal groups. Because intranasally
administered PAF was unable to overcome IPA, modified and combined therapies were introduced. The intraperitoneal
application of PAF in animals with IPA prolonged the survival of the animals only 1 day. Similar results were obtained with
amphotericin B (AMB), with PAF and AMB being equally effective. Combined therapy with AMB and PAF—which are synergistic
in vitro—was found to be more effective than either AMB or PAF treatment alone. As no toxic effects of PAF in mammals have
been described thus far, and, moreover, there are so far no A. fumigatus strains with reported inherent or acquired PAF
resistance, it is worth carrying out further studies to introduce PAF as a potential antifungal drug in human therapy.
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INTRODUCTION
The number of immunodeficient patients is rising as a consequence of
modern therapies, and they are endangered by infections from a wide
spectrum of microbes, including yeasts and filamentous fungi.1 Fungal
infections are the most dangerous among them because their
treatments are often ineffective owing to inherent or acquired
antimycotic resistance of the fungi.2 Aspergillosis is one of the most
challenging infections and is caused by various Aspergillus species,
amongst which the most virulent and most wide-spread species is
Aspergillus fumigatus.3 It can cause several diseases, including asper-
gilloma, allergic bronchopulmonary aspergillosis, and invasive
aspergillosis.4,5 In invasive pulmonary aspergillosis (IPA), hyphae
spread in the lung tissue and cause coagulation necrosis, which makes
round-shaped discrete nodules with hyphae inside, or fused lobular
consolidations can be observed, consisting of acute inflammatory
exudate in the alveoli with fungal proliferation.5 This process can
destroy a lobe or the whole lung, which leads to high mortality.
The therapy for IPA includes surgical removal of the aspergilloma
(fungal balls developed in cavities) and drugs, such as voriconazole,
itraconazole, posaconazole, caspofungin, micafungin or amphotericin
B (AMB).6,7 Mortality remains high even with long-term combination
therapy, and relapse is prevalent.8 Antifungal resistance can evolve
through diverse mechanisms; probably the most important is the
deregulation of antifungal resistance effector genes by point mutations
in their transcriptional regulators or the genes coding for antifungal
targets.9 In the last few years, more and more resistant Aspergillus
strains have been reported (A. fumigatus10 and A. terreus11). For that
very reason and the high mortality of the patients, it would be
important to find new drugs against IPA.
Various eukaryotes, including fungi, produce a wide spectrum of
small antifungal proteins, which are suitable for the development of
new therapeutic agents against fungal diseases.12,13 Penicillium chryso-
genum produces not only penicillin but also a low molecular mass (6.5
kD) protein (PAF, GenBank accession number AAA92718).14 PAF is
stable even under extreme test conditions (pH, high temperature and
proteases)15 and possesses a fungicide effect on various species
including some Aspergillus species, such as A. fumigatus, A. niger and
A. nidulans.16,17 The protein enters sensitive fungi through internaliza-
tion via an endocytotic mechanism18 and elicits the increased
production of harmful reactive oxygen species enhancing the
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oxidation of intracellular molecules, decreases the metabolism of
fungal cells, and triggers disintegration of mitochondrial
membranes.16,19,20
It was shown previously that PAF had no toxic effects on a wide
range of mammalian cells.21 We demonstrated previously in vivo that
intranasally applied PAF did not alter important physiological para-
meters of mice.22 At concentrations that are highly toxic for most
sensitive molds in vitro, the animals neither died because of the
treatment nor were there any side effects observed. It was confirmed
that a detectable amount of PAF accumulated in the lungs, and it kept
its antifungal activity for hours.
In this study, we tested PAF in vivo against pulmonary aspergillosis
in mice. Single or combination therapy with amphotericin B—
showing synergistic effects in vitro—prolonged the survival of animals
suffering from IPA. Our results suggest that further animal investiga-
tions in vivo should be carried out to support the possible therapeutic
application of PAF against aspergillosis in humans.
MATERIALS AND METHODS
Purification of PAF
Purification of PAF was carried out as described previously.21,23
Briefly, P. chrysogenum Q176 was grown in a sucrose (20 g/L) and
NaNO3 (3 g/L) based minimal medium for 96 h at 25 °C with shaking.
After harvesting of the mycelia by centrifugation and separation of the
low molecular weight protein fraction in Amicon Stirred Cells
(V= 50 mL, Biomax PBTK ultrafiltration disks, size exclusion limit
MWCO= 30 000; MILLIPORE, Billerica, MA, USA), PAF was purified
by ion-exchange chromatography on a CM Sephadex Fast Flow
column (2× 18 cm, equilibrated with 50 mM sodium phosphate buffer,
pH= 6.6, flow rate 1 mL/min, t= 4 °C; AMERSHAM-Pharmacia,
Uppsala, Sweden). PAF was eluted with a NaCl gradient (0.05–1 M)
prepared in the equilibrating buffer, and PAF-containing fractions
were dialyzed in phosphate-buffered saline (PBS).
In vitro study assay
Minimum inhibitory concentration (MIC) determination of AMB and
PAF and the drug combination studies were performed according to
CLSI M38-A2 guidelines.24 The final concentrations of the tested
drugs ranged from 0.0625 to 16 μg/mL for AMB, and from 25 to
500 μg/mL for PAF. The MICs of the antifungal agents were
determined after 48 h of incubation at 35 °C as the lowest drug
concentration at which there was complete inhibition of growth. In a
checkerboard assay, combinations of the two drugs were determined
according to the MIC values of the drugs used alone.25 The interaction
of AMB and PAF was assessed by calculating the fractional inhibitory
concentration index (FICI) with the following formula: FICI= ((MIC
A in combination)/MIC A)+((MIC B in combination)/MIC B). The
interaction is synergic if the FICI is ⩽ 0.5; indifferent if the FICI is
40.5 and ⩽ 4; and antagonistic if the FICI is 44.25
Preparation of fungal conidia
Inocula of A. fumigatus AF293 (clinical isolate from human lung
tissue) were prepared by culturing the test organisms on minimal
nitrate medium.26 Freshly grown (6 days) conidia were harvested in
PBS-0.01% Tween 80 and counted in a Bürker chamber.
Animal care
Eight to 12-week-old Balb/c mice of both sexes (weighting 17–25 g)
were used in all in vivo experiments. The animal experiments
conformed to the guidelines of the European Community (86/609/
EEC). The experimental protocol was approved by the institutional
Animal Care Committee of the University of Debrecen (11/2008/DE
MÁB). The mice were housed in plastic cages with mesh covers and
fed with pelleted mouse chow and water ad libitum. Room illumina-
tion was an automated cycle of 12 h light and 12 h dark, and room
temperature was maintained within the range of 22 –25 °C.
Mice infected with A. fumigatus were kept in isolation cages with
high-efficiency particulate air filters. These cages were continuously
ventilated, and slightly negative air pressure was used to prevent
infection from fungal spores. Each cage was inspected at least three
times daily.
Infection of mice with A. fumigatus
Mice were immunosuppressed with 250 mg/kg cyclophosphamide
(Endoxan, Baxter, IL, USA) intraperitoneally (IP) three days before
and one day after infection with A. fumigatus conidia. A total of
3.5 × 106 conidia dissolved in 50 μL PBS was given to mice intranasally
under anesthesia with isoflurane. The number of conidia was chosen
to produce 100% mortality. This was tested in preliminary experi-
ments (Supplementary Figure S1). Gentamicin was added to the water
of the mice (5 mg/kg). The survival of the animals was monitored
three times daily after infection. All infected animals were humanely
terminated if they presented severely reduced mobility (i.e., unable to
reach their water or food) or substantial distress. After the death of
animals, their organs were removed and histological examination was
carried out.
Intranasal PAF treatment of animals suffering from invasive
pulmonary aspergillosis
In five independent experiments, immunosuppressed mice were
randomly divided into three groups from which two were Aspergillus
conidia infected. Among the infected groups the first group was
treated with 5.4 mg/kg PAF (26 mice), the second group with PAF-free
PBS (positive control, 23 mice) intranasally in the final volume of
50 μL. The intranasal application of PAF was described earlier.22
Briefly, mice were slightly anesthetized with isoflurane, then 2.7 mg/kg
PAF dissolved in PBS were administered by pipette into the nose of
the animals in a 50 μL final volume. Under these conditions the
solution reaches the lungs through normal breathing. Treatments
lasted until the death of animals from the day of the infection twice a
day (morning and afternoon). The control group (negative control, six
mice) was not infected but immunosuppressed and treated intrana-
sally with PAF-free PBS twice a day. Some animals from the infected
group were killed 3 days after the infection, and their organs were
examined histologically.
Intraperitoneal PAF treatment of healthy animals
Mice were randomly divided into two groups. The first group (n= 8)
was treated IP with 5.4 mg/kg PAF dissolved in 100 μL PBS twice a day
and intranasally twice a day with 2.7 mg/kg PAF dissolved in 50 μL
PBS for seven days. The second (control) group (n= 8) was treated
with PAF-free PBS in the same way. On the eighth day, some animals
were killed and the organs were removed for histological examination.
On the first and last days of the experiment, body weight was
measured, blood was collected, and blood cell count and other plasma
parameters were determined.22
Combined treatment with PAF and amphotericin B of animals
suffering from invasive pulmonary aspergillosis
In two independent experiments, immunosuppressed mice were
randomly divided into five groups (all together 11 mice per group).
Animals in four groups were Aspergillus conidia infected, the non-
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infected group was the negative control. All antifungal treatment
started on the day of the fungal infection and lasted till the death of
the animals. The first infected group was treated with PAF and
amphotericin B-desoxycholate (Fungizone, Bristol-Myers Squibb,
Montreal, QC, Canada), the second group with PAF, the third group
with AMB and the positive control group only with PBS. A total of
5.4 mg/kg PAF dissolved in PBS was injected IP twice a day in 100 μL
final volume, and 50 μL were administered by pipette into the nostrils
of the animals under anesthesia once a day. One hundred microliters
AMB were injected IP in 5 mg/kg concentration three times as follows:
one, two and four days after the fungal infection.27 The animals in the
negative control group were treated only with PBS in the same way as
the PAF-treated group. After the death of the infected animals, their
organs were removed for histological examination.
Histological examination and lung injury score
To explore the possible positive effects of intranasal and intraper-
itoneal application of PAF, the lungs, the kidneys and the liver of the
animals were examined histologically as described earlier.22 Briefly,
tissue samples were fixed in 8% buffered formalin (24 h) and
embedded in paraffin wax (Shandon Pathcenter, Thermo-Shandon,
Astmoor, WA, USA). Hematoxylin–eosin (H&E) and periodic acid–
Schiff (PAS) staining was performed on 4 μm thick cut sections. The
alveolar exudate/edema and hemorrhage were scored on a scale of 0–3
(0, absent; 1, mild; 2, moderate; 3, severe) from five randomly chosen
fields in each sample.
Blood collection and cell counting
Blood samples were taken as described earlier.22 Briefly, 200 μL blood
was collected at the beginning and at the end of the 1-week long
experiment from control animals (n= 8) and animals treated IP and
intranasally with 10.8 mg/kg and 5.4 mg/kg doses of PAF (n= 8),
respectively. Anticoagulated whole blood was analyzed by a Siemens
Advia-120 hematology analyzer (Deerfield, IL, USA). The numbers of
white blood cells and neutrophil granulocytes, the levels of liver
enzymes and ions in the plasma were determined to explore the
possible toxic effects of PAF.
Chemicals and statistical analysis
Chemicals, unless otherwise stated, were purchased from Sigma
(St. Louis, USA) and were of analytical grade. Averages were expressed
as the means± standard error (SE) of the mean. The differences
between control and treated animals were assessed using one-way
analysis of variance (ANOVA) and all pairwise multiple comparison
procedures (Student–Newman–Keuls method). The F test was used to
test significance, and a P value of o0.05 was considered statistically
significant.
Percentage survival was computed with the Kaplan–Meier method.
The mortality rate as a function of time was fitted to a Gompertz
mortality rate equation.28 The equation is as follows:
Rm ¼ R0  plð Þ ´ exp a ´ tð Þ; ð1Þ
where R0 is the initial mortality rate, pl is plateau at the end of
experiment, α is the Gompertz parameter and t is the time. The
significance of differences between survival curves was assessed as the
statistically accepted differences in the fitted Gompertz parameter (α)
and with the log-rank (Mantel–Cox) test. The results were evaluated
with GraphPad Prism 6.0 software (La Jolla, CA, USA).
RESULTS
Survival and histological examination of animals suffering from
pulmonary aspergillosis treated intranasally with PAF
As the most likely application of PAF in human therapy is expected to
be the treatment of lung aspergillosis, which implies the administra-
tion of the drug via the airways, we simulated this procedure by
introducing PAF intranasally to mice at a high concentration (5.4 mg/kg).
Infected animals suffering from IPA were evidently sick, moved slowly
and their fur was matted. Moreover, their weight decreased signifi-
cantly (Table 1). PAF delayed the death of animals by ~ 1 day, but all
animals had died by day nine (Figure 1A). Log-rank analysis showed
no significant differences (P= 0.86) between the survival curves. In
contrast with this, all of the control non-infected mice, treated only
with PAF in PBS, showed 100% survival and their body weight was
stable (Table 1). Overall, intranasal PAF treatment did not increase
significantly (F(1,47)= 0.23, P= 0.63) the average survival of the
animals (Figure 1B).
Histological examination of the lungs displayed severe pulmonary
lesions characterized by multifocal to coalescent infiltrations of
Table 1 Average body weight of mice in different treatments
Relative time to infection
F statistics
−1 day +3 days
Intranasal treatment
Negative control (n=6) 17.9±0.7 17.2±0.4 F1,10=0.13, P=0.73
Positive control (n=23) 17.1±0.4 13.8±0.3a F1,44=42.9, P=2×10−4
PAF-treated (n=26) 17±0.4 13.7±0.4a F1,50=41.1, P=2×10−4
Intranasal and IP treatment
Negative control (n=11) 18.5±0.2 17.2±0.7 F1,20=4.24, P=0.06
Positive control (n=11) 18.5±0.1 11.9±0.1a F1,20=338, P=2×10−8
PAF-treated (n=11) 17.5±0.5 12.2±0.3a F1,20=73.6, P=6×10−5
AMB-treated (n=11) 18.6±0.2 12.6±0.3a F1,20=192, P=7×10−8
PAF+AMB-treated (n=11) 19.4±0.5 12.7±0.3a F1,20=115, P=5×10−6
Abbreviations: Amphotericin B, AMB; intraperitoneally, IP.
aDenotes significantly different from body weight before fungal infection (−1 day).
Values are given in grams. Animals in the negative control groups were immunosuppressed but not infected by A. fumigatus.
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macrophages and neutrophils associated with vascular phenomena
(thrombi, necrosis and hemorrhages) and alveolar and bronchiolar
epithelial cell necrosis. There were no remarkably positive effects in
the lungs following intranasal application of the antifungal protein. In
positive control mice, a high number of proliferating hyphae (Figure 2,
left panels) and coagulation necrosis were observed in the blood
vessels, septa, bronchioles and alveoli. In the lungs from mice treated
intranasally with PAF, hyphae were also frequently observed in the
bronchioles and the alveoli. However, invasion of hyphae into blood
vessels was not observed (Figure 2, right panels). The lung injury score
was significantly higher in both cases (6± 0 and 5.3± 1.2 in positive
control and PAF-treated mice, respectively) than in uninfected
negative control animals (0.3± 0.3; F(2,6)= 18.5, P= 0.003). The
PAF-treated animals had values slightly but not significantly lower
than the untreated ones (F(1,4)= 0.31, P= 0.61). It is important to
mention, however, that we did not find fungal infection in the kidneys
or in the liver (data not shown).
Effects of intraperitoneal application of PAF on healthy animals
As the nasal application of PAF was not as successful as expected, the
drug was administered IP as well. Control non-fungal-infected mice
were treated IP with 0 and 5.4 mg/kg doses of PAF twice a day for
1 week. Blood samples were collected at the beginning and end of the
experiment (Table 2).
Although the total white blood cell count decreased slightly
(F(1,14)= 35.5, P= 3×10− 5), the percentage of neutrophils remained
unchanged (F(1,14)= 0.71, P= 0.41). Furthermore, the concentration
of liver enzymes and ions in the blood did not show significant
(0.01oF(1,14)o4.39, 0.08oPo0.93) elevation/alteration after PAF
treatment. There was no significant change in the weight of the
animals during the application of PAF. The average weight of the
animals was 17± 0.3 g at the beginning and 17.2± 0.4 g at the end
(F(1,14)= 0.19, P= 0.67). These results suggest that the intraperitoneal
application of PAF neither induced any overall changes in the animals
nor initiated an overall immune response, similarly to the nasal
application.
Combined treatment of animals suffering from pulmonary
aspergillosis
To increase the positive effects of PAF, its intranasal application was
complemented with intraperitoneal injection. The combined applica-
tion of PAF and AMB was also tested. Before the in vivo application,
an in vitro drug combination assay of AMB plus PAF was performed.
With AMB and PAF alone, the MIC values against A. fumigatus AF293
proved to be 1 and 300 μg/mL, respectively. FICI values indicated an
in vitro synergic effect when AMB was combined with PAF. The FICI
value calculated from the individual and combined MICs (0.25 μg/mL
of AMB and 50 μg/mL of PAF) of the drugs is 0.42. Figure 3A presents
the survival of infected mice that were treated with PAF, amphotericin
B (5 mg/kg), and both antifungal drugs concomitantly. It is clearly
visible in Figure 3B that although neither PAF nor AMB alone
increased survival, the combined application resulted in a remarkable
extension of life expectancy. In this experiment, all infected animals
died within 7 days independently of the treatment they received. In the
untreated infected group, more than 80% of the animals died after
5 days. Importantly, on this day more than 50% of the PAF or AMB-
treated animals were still alive. It is noteworthy that in the group
receiving the combined treatment, only 30% of the animals died by
the 5th day. After 6 days, all PAF-treated animals died, meanwhile 9%
of the AMB-treated animals and 27% of the combined treatment
animals were alive. Summing up, individual PAF or AMB treatment
extended the survival of the animals by 1 day, and some animals in the
combined treatment group lived 2 days longer than those in the
untreated group.
To test the differences between the survival curves, Equation (1) was
fitted to the data points (Figure 3A). Although the Gompertz mortality
rate was high (α= 1.596) in the positive control group, it was
significantly lower in the PAF (α= 0.6882, Po0.001) and AMB
(α= 0.6146, Po0.001) treated groups. Furthermore, the combined
treatment significantly slowed down the mortality (α= 0.4831,
Po0.001) when compared with the untreated group. As all animals
died in all groups, the plateaus of the curves were assumed to be zero.
The log-rank test also proved that the survival curves of the treated
groups are significantly different from that of the untreated one
(P= 0.04).
There was no significant difference in the average survival time
(Figure 3B) between the single treatment groups (F(1,20)= 0.20,
P= 0.66). PAF treatment alone caused a close to significant increase
(F(1,20)= 4.02, P= 0.06) in the average survival of the animals.
However, AMB alone (F(1,20)= 4.88, P= 0.04) and the combined
PAF and AMB treatment (F(1,20)= 6.99, P= 0.02) increased signifi-
cantly the lifetime of the animals.
These observations were validated by histological examination. In
the lungs from IP PAF-treated mice, a number of proliferating hyphae
(Figure 4, left panels) and coagulation necrosis were noted in
bronchioles and alveoli. In the lungs from mice treated with PAF
and AMB, hyphae were not observed (Figure 4, right panels). H&E
staining of sections confirmed less extensive inflammation in the
combined AMB and PAF-treated animals (Figures 4A and 4B). In
addition, PAS staining proved the manifestation of extensive fungal
infection in the single antimycotic (either PAF or AMB) treated
animals and the lack of infection when PAF and AMB were used in
combination (Figures 4C and 4D). Furthermore, the lung injury score
was lower in the combined treatment group (4± 0.6, F(1,5)= 4.96,
P= 0.08) than in the control group (6.3± 0.8). However, the score of
the PAF-treated group (5± 0.0) was almost identical to that of AMB-
treated animals (5.3± 0.6, F(1,4)= 0.25, P= 0.64). None of them was
significantly lower than the control value (F(2,7)= 1.11, P= 0.38.)
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Figure 1 Survival of mice suffering from pulmonary aspergillosis with and
without nasal PAF treatment. (A) Survival curves obtained from five
independent experiments of untreated (black ●, n=23) and 5.4 mg/kg PAF-
treated (gray ▲, n=26) mouse groups infected intranasally with 3.5×106
Aspergillus fumigatus conidia/50 μL phosphate-buffered saline (PBS). The
negative control (no fungal infection, blue ▼, n=6) shows 100% survival.
(B) Average survival time of fungal infected mice without (positive control)
and with PAF treatment (PAF). Error bars represent the standard error.
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Combined treatment with a reduced concentration of AMB
To investigate the efficacy of PAF, the previous experiment was
repeated with a reduced concentration (2.5 mg/kg) of AMB. The
combined application of PAF and AMB (n= 6) was compared with
the single AMB-treated group (n= 11). Figure 5A shows that AMB
alone delayed but did not prevent the death of the animals. After
8 days, all AMB-treated animals died, whereas its combined applica-
tion with PAF not only delayed further the development of aspergil-
losis but also resulted in the survival of an infected mouse (16.6%). In
contrast, all infected and untreated animals (n= 12) died within
Positive control PAF
200 µm
100 µm 
100 µm 
200 µm
100 µm 
100 µm 
200 µm 200 µm
Figure 2 Histological investigation of lung tissue from mice suffering from pulmonary aspergillosis with and without nasal PAF treatment. Representative
images show histological features of lung tissues stained with hematoxylin–eosin (H&E) (A and B) and PAS (C and D) from untreated positive control (left
column) and 5.4 mg/kg PAF-treated (right column) mice suffering from invasive pulmonary aspergillosis (IPA) at two magnifications. Extensive fungal growth
and tissue damage are evident in the untreated IPA mice. Less extensive fungal infection is present in the PAF-treated mice. Arrows show fungal balls with
high density fungi and proliferating hyphae. See the strong magenta colored hyphae in C and D.
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seven days. The combined PAF and AMB treatment extended the
survival of the animals by 1 day, and one animal recovered from
aspergillosis.
Because the animals started to die earlier (at 2nd day) in the positive
control group, the analysis of survival curves resulted in a slow
(α= 0.2822) Gompertz mortality rate. It was significantly higher in
AMB (α= 0.4292, P= 0.002) treated groups, but the death of the
animals started only at the 3rd day. In both cases the final number of
animals (plateau) was 0. However, the combined treatment delayed
the start of animal death to the 4th day, increased the survival of
animals (plateau is 14.1%) and resulted in a significantly different
mortality rate (α= 0.4689, P= 0.007) when compared with the
untreated group. However, the log-rank test only showed significant
difference for the trend (P= 0.03) and not between the survival curves
themselves (P= 0.09).
There was no significant difference in the average survival
time (Figure 5B) between the single treatment and positive control
group (F(1,21)= 1.79, P= 0.20). However, the combined PAF and AMB
treatment (F(1,16)= 5.48, P= 0.03) increased the lifetime of the animals
significantly.
DISCUSSION
The present study compared the in vivo antifungal activity of PAF
when administered either intranasally or IP alone or in combination
with amphotericin B—as an in vitro interaction study confirmed that
the effect of these drugs is synergistic against A. fumigatus—in an
immunocompromised mouse model of invasive pulmonary aspergil-
losis initiated by A. fumigatus. The model was highly reproducible, and
all untreated animals died within 9 days following the fungal infection.
Although PAF is a protein, it is highly stable,15 and, hence, it is easy
and safe to prepare it for administration independent of the mode of
application. In the case of nasal application, a concentration high
enough to have antifungal activity in vitro was determined in the
lungs.22 However, independent of the mode of application, the protein
was undetectable in serum (data not shown). Notably, accumulation
of PAF over time was not observed, which was most likely the
consequence of its short half-life within the body. It should be noted
that blood samples were taken 120 min after the last intraperitoneal
administration of the drug and that PAF is small enough to be filtered
by the glomeruli and thus excreted by the kidneys. On the basis of this,
to achieve detectable concentrations of PAF in the serum of mice, the
protein should be administered in doses higher than those used in our
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Figure 3 Survival of mice suffering from pulmonary aspergillosis with
and without intraperitoneal PAF and amphotericin B (AMB) treatment.
(A) Survival curves obtained from two independent experiments of untreated
(black ●, n=11), PAF-treated (gray ▲, n=11), 5 mg/kg AMB-treated (red
♦, n=11) and combined PAF-AMB-treated (green ■, n=11) mouse groups
infected intranasally with 3.5×106 A. fumigatus conidia/50 μL PBS. The
negative control (no fungal infection, blue ▼, n=11) shows 100% survival.
Lines starting at day 4 in the infected groups represent the best fit of
Equation (1) to the averages. (B) Average survival time of fungal infected
mice without (positive control) and with PAF, AMB and combined (PAF
+AMB) treatment. *Denotes significantly different from positive control
(P=0.06, P=0.04 and P=0.02 for PAF, AMB and PAF+AMB treatment,
respectively). Error bars represent the standard error.
Table 2 Important parameters of plasma from control and IP PAF-treated mice
Control PAF F statistics
White blood cells (G/L) 9.75±0.51 5.87±0.41a F1,14=35.53, P=3×10−5
Neutrophils (%) 20.1±2.6 23.2±2.5 F1,14=0.71, P=0.41
Creatinine (μmol/L) 14.1±2.1 13±1.5 F1,14=0.20, P=0.66
Total bilirubin (mmol/L) 1.68±0.11 1.63±0.11 F1,14=0.17, P=0.70
AST-GOT (U/L) 389.5±45.2 238.8±56 F1,14=4.39, P=0.08
ALT-GPT (U/L) 208.6±63.7 82.3±39.4 F1,14=1.73, P=0.22
Albumin (g/L) 35.4±0.5 37.3±1.3 F1,14=1.83, P=0.20
Ca (mmol/L) 2.41±0.01 2.49±0.07 F1,14=1.23, P=0.31
K (mmol/L) 7.73±0.38 7.56±0.41 F1,14=0.08, P=0.79
Na (mmol/L) 149.4±0.9 149.5±0.6 F1,14=0.01, P=0.93
Cl (mmol/L) 109.3±0.7 108.3±0.6 F1,14=1.04, P=0.33
Abbreviations: Aspartate aminotransferase, AST; alanine transaminase, ALT; glutamate oxaloacetate transaminase, GOT; glutamate pyruvate transaminase, GPT; intraperitoneally, IP.
aNone of the values, except white blood cell count, following PAF treatment were significantly different from those in the control.
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experiments. There may be a threshold therapeutic concentration for
the successful medication of IPA, which should be determined in
future studies.
The intraperitoneal administration of PAF was beginning to prevent
the spread of fungi in the lungs around days 5 and 6 post-infection,
but finally it was not able to overcome the fungal invasion. It is
remarkable that PAF alone was almost as effective as the lower
(2.5 mg/kg) concentration AMB, an antimycotic used frequently in the
medication of IPA.5,29 Furthermore, the combined application of PAF
and AMB was clearly superior to either single antimycotic (PAF or
PAF PAF+ AMB
200 µm
200 µm 200 µm
200 µm
100 µm 
100 µm 100 µm 
100 µm 
Figure 4 Histological investigation of lung tissue from mice suffering from pulmonary aspergillosis with intraperitoneal PAF and amphotericin B treatment.
Representative images show histological features of lung tissues stained with H&E (A and B) and PAS (C and D) from PAF-treated (left column) and PAF
plus amphotericin B (AMB)-treated (right column) mice suffering from invasive pulmonary aspergillosis (IPA) at two magnifications. Extensive fungal growth
and tissue damage are evident in the PAF-treated IPA mice (arrows). Note the lack of fungal balls and hyphae in the lungs of animals with combined
treatment.
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AMB) treatment when increased survival times were considered. The
dose of AMB (5 mg/kg) used in this model was not able to prevent the
progression of IPA in mice. In human treatment, AMB is usually
administered in intravenous (IV) infusion for 1–2 weeks, and its
typical dosage is 3 mg/kg·day. With higher dosage of AMB (10 mg/
kg·day), the incidence of nephrotoxicity increases.30 However, in
patients with IPA, no difference was observed in efficacy between
the low and high dosage of AMB showing ~ 50% positive effect. A
comparative study with posaconazole and AMB found that although
the survival with posaconazole was 70%–90%, it was only 0–50% with
AMB.31 The efficiency of AMB and anidulafungin was also compared,
and both antimycotics could prolong survival, but finally at least 90%
of the animals died in every group.32 These findings are in good
accordance with our observations.
We have to note notwithstanding that the intraperitoneal admin-
istration of AMB is less clinically relevant, but its synergic effects with
PAF could also be investigated in our animal model. It was shown
previously that the distribution of AMB in the lungs is significantly
different when administered IP versus intravenously.33 As IP admin-
istration resulted in a higher level of AMB in the lungs than the IV
route, in further animal studies the applied concentration should be
different than was used here. It is also possible that the histological
changes we observed were partly the consequence of the accumulation
of AMB, although we used AMB at a low concentration and only
three times.
It is also promising that the combined application of PAF with
lowered AMB (2.5 mg/kg) was as effective or even better than the
combined treatment with the high concentration AMB. This finding
raises the possibility of combined treatment with reduced AMB and
thus decreased toxicity, which has been observed in mice suffering
from IPA.34 In contrast, no toxicities or side effects of PAF have been
reported thus far.22
Similar to other pathogenic fungi, Aspergillus spp. can develop
resistance against different antifungal agents. For example, itraconazole
resistance was first reported in 1997,35 and more than 50% of the
strains resistant to itraconazole were cross-resistant to other azoles,
such as voriconazole and posaconazole, which are primary drugs in
antifungal therapies.10 Resistance to antimycotics can emerge through
different mechanisms, such as increased drug reflux, modification or
over-expression of target enzymes, up-regulation of homeostatic
stress-response pathways, exogenous cholesterol import or altered
drug uptake.
Owing to the emergence and spread of resistance towards frequently
used antifungals, there is an urgent need for new types of antimy-
cotics effective against human opportunistic Aspergillus spp. Our study
demonstrated for the first time that PAF has potential in vivo against
IPA even when administered at relatively low concentrations.
Furthermore, the fact that AMB interacted synergistically with
PAF in vitro indicated that such combinations may also have good
efficacy in the treatment of neutropenic patients suffering from IPA.
Future in vivo studies should aim at shedding light on further
interactions of antimycotic drugs with PAF and determining the
threshold concentrations at which IPA could be blocked or even
reversed.
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